Ojjaara helps patients with myelofibrosis by reducing spleen size, easing symptoms, and improving anemia to boost independence from blood transfusions. Ojjaara (momelotinib) is the first treatment of ...
About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to treat asymptomatic or minimally ...
Please provide your email address to receive an email when new articles are posted on . The combination of pelabresib plus ruxolitinib significantly increased the proportion of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results